Lung cancer is the number one cause of deaths among all cancers[@b1]. Platinum-based chemotherapy, one of main treatments for this disease, often fails due to drug resistance of tumors. The excision repair cross-complementing 1 (ERCC1) protein plays a key role in the nucleotide excision repair system, which is primarily responsible for cancer cell resistance to platinum-based drugs. The expression level of the ERCC1 protein is an important marker in predicting platinum drug resistance in tumors; ERCC1-positive patients are refractory to platinum-based chemotherapy[@b2]--[@b4].

When the efficacy of chem otherapy reaches to a plateaus[@b5], lung cancer-targeting drugs, such as tyrosine kinase inhibitors of the epidermal growth factor receptor (EGFR-TKIs)[@b6]--[@b9] and anti-vascular endothelial growth factor (VEGF) drugs[@b10],[@b11], have achieved good outcomes. Increasing evidence suggests that potential biological markers, including *EGFR* gene mutation, amplification, or protein expression, are associated with EGFR-TKI drug efficacy[@b6]--[@b9], whereas *K-Ras* mutations are closely related with drug resistance [@b12],[@b13]. VEGF is the most important regulatory factor for tumor angiogenesis, and its protein expression is associated with poor prognosis[@b14],[@b15] and better efficacy of anti-angiogenic drugs[@b16] on non--small cell lung cancer (NSCLC). Therefore, targeted therapy and chemotherapy for cancer are based on different molecular mechanisms.

In the future, treatment options for NSCLC patients will be more dependent on precise molecular characterization. The National Comprehensive Cancer Network (NCCN) guidelines state that NSCLC patients with mutated *EGFR* and wild-type K-Ras should be treated with EGFR-TKIs in clinic. However, the majority of patients treated with EGFR-TKIs were non-smoking female patients with adenocarcinoma. Moreover, molecular studies of EGFR-TKI treatment have been mainly focused on squamous cell carcinoma and adenocarcinoma[@b7]--[@b9]. Large cell lung carcinoma (LCLC), a pathologic type of NSCLC, has been rarely studied. How targeted therapy and chemotherapy are correlated with their associated genes, and how patients with optimal outcomes for targeted therapy are related to those with optimal outcomes for chemotherapy remain unknown. In addition, the correlations of these drug-associated genes to the prognosis after targeted therapy and chemotherapy are still unclear. In this study, we correlated the gene statuses of *EGFR, K-Ras, ERCC1*, and *VEGF* in 60 biopsies from LCLC patients with their prognoses, explored the molecular basis of targeted therapy, and discussed relationship between targeted therapy and chemotherapy.

Materials and Methods {#s2}
=====================

Patients {#s2a}
--------

Sixty paraffin-embedded tissue samples were collected from patients with LCLC treated between February 1993 and July 2009 at the Tianjin Medical University Cancer Institute and Hospital. The pathology of each patient was re-reviewed. No patient received targeted drug therapy. Patients consisted of 44 men and 16 women who were 30 to 76 years old with a median age of 58 years. Forty-five (75.0%) patients had a smoking history, which was defined as smoking one or more cigarettes per day continuously for 3 or more months.

DNA extraction and mutation analysis {#s2b}
------------------------------------

DNA was isolated from the paraffin-embedded tissues using an E.Z.N.A.™ Tissue DNA kit (OMEGA, US) according to the manufacturer\'s instructions. Nested polymerase chain reaction (PCR) was used to amplify *EGFR* exons 18--21 and *K-Ras* exon 2[@b17]. The PCR was run at 94°C for 60 s, 35 cycles of 58°C for 30 s and 72°C for 30 s, followed by an extension step at 72°C for 10 min. After purification, DNA was directly sequenced using the ABI Prism 3730 DNA sequencer (Applied Biosystems, Foster City, CA).

FISH detection of EGFR gene amplification {#s2c}
-----------------------------------------

The LSI *EGFR* SpectrumOrange/chromosome 7 (CEP7) SpectrumGreen probe (Vysis; Abbott Laboratories, Downers Grove, IL) was used according to the manufacturer\'s instructions. Paraffin-embedded LCLC sections (4 µm) were baked, deparaffined by washing in xylene, and dehydrated in 100% ethanol, and then incubated in pretreatment liquid (paraffin pretreatment kit) for 20 to 25 min at 80°C. Next, sections were digested with proteinase K (0.25 mg/mL in 2 × SSC; pH7.0) for 15 to 25 min at 37°C, after which EGFR/CEP7 probes were placed at the tumor regions for hybridization in the instrument. The hybridization was performed as denaturation at 73°C for 10 min, incubation at 37°C 16 h, followed by DAPI staining (0.15 mg/mL, Vector Laboratories, Burlingame, CA). Evaluation was made according to reported literature[@b7]. Specifically, samples with high copy number (more than 40% of cells containing 4 or more gene copies) and gene amplification (cells containing *EGFR* gene clusters and with a ratio of *EGFR* gene and chromosomes ≥ 2, or more than 10% of cells containing 15 or more gene copies) were regarded as *EGFR* FISH-positive.

Immunohistochemical detection of protein expression {#s2d}
---------------------------------------------------

The 4-µm sections were baked, dewaxed, and rehydrated with gradient ethanol followed by overnight incubation at 4°C with primary mouse anti-human EGFR monoclonal antibody (31G7, Zymed Laboratories, South San Francisco, CA), mouse anti-human VEGF monoclonal antibody (1:100 dilution, VG-1, abcam, Hong Kong), and mouse anti-human ERCC1 monoclonal antibody (1:50 dilution, 8F1, abcam, Hong Kong), respectively, in a final volume of 100 µL antibody dilution solution. Next, the samples were incubated with 100 µL anti-mouse or anti-rabbit secondary antibody (ChemMate™ EnVision™ Detection Kit, Dako, USA) for 30 min at 37°C. After staining, the samples were sealed. EGFR [@b8], ERCC1 [@b18], and VEGF [@b14] expression were evaluated according to reported literature. A sample which had more than 10% of cells with membrane EGFR staining was regarded as EGFR-positive.

Statistical methods {#s2e}
-------------------

Pearson\'s Chi-square or Fisher\'s method in SPSS 13.0 software was used to examine relationship between biological markers and clinicopathologic features. The Kaplan-Meier method was used for survival analysis, and the log-rank method was used to test difference. The Cox proportional regression model was used for multivariate analysis, and the Spearman rank correlation coefficient analysis was used to analyze marker correlation. *P* \< 0.05 was considered statistically significant.

![Kaplan-Meier overall survival curves of patients with large cell lung cancer.\
A, the overall survival rate of patients with lymph node metastasis is lower than that of patients without lymph node metastasis; B, the overall survival rate of patients with early TNM stage disease is higher than that of patients with advanced stage disease.](cjc-30-07-497-g001){#cjc-30-07-497-g001}

Results {#s3}
=======

Clinicopathologic features and biomarkers of LCLC and their correlations with prognoses {#s3a}
---------------------------------------------------------------------------------------

A better prognosis trend was found in the patients with smoking history (*P* = 0.067), tumor diameter \< 3 cm (*P* = 0.083), or low VEGF expression (*P* = 0.098), though these findings were not statistically significant. Univariate analysis showed that lymph node metastasis (*P* = 0.049) and advanced stage (*P* \< 0.001) were associated with poor prognosis ([Table 1](#cjc-30-07-497-t01){ref-type="table"}, [Figure 1](#cjc-30-07-497-g001){ref-type="fig"}). Multivariate analysis showed that TNM stage (HR = 3.347, 95% CI = 1.791--6.254, *P* \< 0.001) was the only independent prognosis factor. The biomarker features had no correlation with prognosis ([Table 1](#cjc-30-07-497-t01){ref-type="table"}).

Correlations of biomarkers to clinicopathologic features of LCLC {#s3b}
----------------------------------------------------------------

All samples were examined with related markers, and FISH detection failed in 9 cases. One sample (1.7%) contained *EGFR* gene L858M mutation, and 3 (5.0%) harbored *K-Ras* mutations (2 cases of G12C mutation and 1 case of G12D mutation). Ten samples (10/51, 19.6%) were *EGFR* FISH-positive, exhibiting high Polyploidy (6/51, 11.8%) or gene amplification (4/51, 7.8%). Immunohistochemistry showed that positive rates for EGFR, ERCC1, and VEGF proteins were 38.3%, 56.7%, and 70.0%, respectively ([Figure 2](#cjc-30-07-497-g002){ref-type="fig"}). VEGF expression was commonly found in samples with lymph node metastasis (84.6% vs. 58.8%, *P* = 0.046) and cancer stage III--IV (84.0% vs. 60.0%, *P* = 0.052). *EGFR* FISH status, EGFR protein expression, *K-Ras* mutations, and ERCC1 expression were not correlated with patient sex, age, smoking history, tumor size, TNM stage, and lymph node metastasis ([Table 2](#cjc-30-07-497-t02){ref-type="table"}). The data on *EGFR* mutations is statistically meaningless due to insufficient mutated samples.

The relationship among markers {#s3c}
------------------------------

*EGFR* amplification was positively correlated with EGFR protein expression (*r* = 0.390, *P* = 0.005). The rate of *EGFR* amplification was higher in ERCC1-positive samples than in ERCC1-negative samples (23.3% vs. 14.2%). The positive rate of ERCC1 protein expression in samples with *EGFR* amplification was 70%, suggesting a co-positivity trend of the two markers, but this result was not statistically significant (*P* = 0.433). In addition, *K-Ras* mutations were often observed in ERCC1-negative samples (*P* = 0.411), VEGF-positive samples (*P* = 0.252), and samples without *EGFR* amplification (*P* = 0.486), though, similarly, these data were not statistically significant. The positive rate of VEGF in ERCC1-negative samples was as high as 65.3%, but this result was not statistically significant. A meaningful analysis could not be completed for the low rate of *EGFR* mutations.

###### The basic clinicopathologic features and survival of patients with large cell lung cancer (LCLC)

  Variable                   Cases (%)   Median OS (months)   Survival rate (%)   *P* value          
  ------------------------- ----------- -------------------- ------------------- ----------- ------- -------
  Sex                                                                                                 0.590
   Male                      44 (73.3)           27                 68.2            32.0      27.0   
   Female                    16 (26.7)           23                 70.8            38.2      30.2   
  Age                                                                                                 0.744
   ≥ 60 years                25(41.7)            31                 76.0            41.7      26.0   
   \< 60 years               35 (58.3)           21                 65.7            42.0      34.0   
  Smoking history                                                                                     0.067
   Smokers                   45 (75.0)           40                 73.3            42.2      36.2   
   Non-smokers               15 (25.0)           18                 60.0            11.4        0    
  Tumor size                                                                                          0.083
   \< 3 cm                    3 (5.0)            54                 100.0           100.0      --    
   ≥ 3 cm                    57 (95.0)           24                 68.4            37.9      26.5   
  Lymph node metastasis                                                                               0.014
   No                        34 (56.7)           48                 79.4            53.0      47.5   
   Yes                       26 (43.3)           18                 57.7            23.8        0    
  TNM stage                                                                                           0.001
   I                         25(41.7)            --                 87.6            63.0      56.0   
   II                        10 (16.7)           40                 70.0            35.0        0    
   III                       19(31.7)            16                 57.9             9.2        0    
   IV                        6 (10.0)            3                  16.7              0         0    
  *EGFR* mutation                                                                                     0.267
   Positive                   1 (1.7)            65                 100.0           100.0     100.0  
   Negative                  59 (98.3)           24                 69.5            40.0      28.3   
  EGFR expression                                                                                     0.943
   Positive                  23 (38.3)           24                 78.3            35.0      29.2   
   Negative                  37(61.7)            31                 64.9            39.9      31.9   
  *EGFR* amplification \*                                                                             0.947
   Positive                  10 (19.6)           18                 70.0            35.5      31.2   
   Negative                  41 (80.4)           38                 70.7            46.0      26.8   
  *K-Ras* mutation                                                                                    0.656
   Positive                  3 ( 5.0)            40                 66.7            66.7      33.3   
   Negative                  57 (95.0)           24                 68.4            39.5      30.7   
  ERCC1 expression                                                                                    0.825
   Positive                  34 (56.7)           24                 67.6            38.0      33.2   
   Negative                  26 (43.3)           27                 69.0            39.9      26.6   
  VEGF expression                                                                                     0.098
   Positive                  42 (70.0)           21                 69.0            34.0      17.0   
   Negative                  18 (30.0)           38                 66.2            48.0      34.8   

OS, overall survival; *EGFR*, epidermal growth factor receptor; *ERCC1*, excision repair cross-complementation group 1; *VEGF*, vascular endothelial growth factor. "--" indicates that the data have not yet been determined. \* Fluorescence *In situ* hybridization (FISH) failed to detect *EGFR* in 9 cases, so the total cases were 51.

Discussion {#s4}
==========

LCLC, which has an incidence of about 3%, is associated with poor prognosis[@b19]. Currently, there is no effective treatment available for this disease. This study showed that LCLC occurred more frequently in male smokers, but sex and smoking history were not correlated with the prognosis. In addition, smokers had longer median overall survival (OS) than did non-smoker patients, presumably because of the small sample size and unevenly collected data.

The impact of *EGFR* amplification and EGFR protein expression on the prognosis of patients with NSCLC is still unclear. A previous meta-analysis indicated that EGFR-positive patients had worse prognosis than EGFR-negative patients (HR = 1.14, 95% CI = 0.94--1.39)[@b20], and Jeon *et al.*[@b21] reported that non-adenocarcinoma patients with *EGFR* amplification had poor prognosis. Our study indicated that *EGFR* amplification and protein expression were not correlated with prognosis of LCLC, consistent with other reports[@b22],[@b23]. Mutations of *EGFR/K-Ras* and protein expression of ERCC1/VEGF had no impact on the prognosis of patients. Only lymph node metastasis (*P* = 0.014) and TNM stage (*P* \< 0.001) were found to affect prognosis, and multivariate analysis showed that only TNM stage (*P* \< 0.001) affected prognosis.

![Epidermal growth factor receptor (EGFR), excision repair cross-complementation group 1 (ERCC1), and vascular endothelial growth factor (VEGF) protein expression detected by immunohistochemistry and EGFR amplification detected by fluorescence in situ hybridization in large cell lung cancer.\
A, positive immunoreactivity of EGFR (in yellow) is evident in the membrane of tumor cells (×400). B, positive expression of ERCC1 protein was detected in the nuclei of cancer cells (×400). C, immunoreactivity for VEGF was detected predominantly in the cytoplasm of tumor cells (×400). D, *EGFR* amplification was detected by dual-color FISH assay with probes for EGFR (red) and chromosome 7 (CEP7, green). FISH-negative tumor cells show two red and two green signals (×1000). E, cells with amplification show an excess of red signals (×1000).](cjc-30-07-497-g002){#cjc-30-07-497-g002}

Suzuki *et al*.[@b23] reported that EGFR expression was related to lymph node metastasis (*P* = 0.028) and pathologic stage (*P* = 0.0046). Cappuzzo *et al.* [@b7] reported that high *EGFR* gene copy numbers were often observed in females (*P* = 0.04) and non-smoking patients (*P* = 0.001). In consistence with most reports [@b6],[@b7],[@b22], however, we did not find that *EGFR* copy number or protein expression level were correlated with sex, smoking history, TNM stage, and lymph node metastasis, suggesting that the pathologic relationship of *EGFR* gene copy number and expression level is not as prominent as *EGFR* mutations mostly found in Asia, women, non-smoking or adenocarcinoma patients[@b8],[@b18],[@b24]. We found that *K-Ras* mutations and ERCC1 protein expression were not statistically correlated with clinicopathologic features of LCLC. However, we found that VEGF protein expression occurred more commonly in patients with lymph node metastasis (*P* = 0.052) and poor prognosis (*P* = 0.098), suggesting that it may be a negative prognostic factor of LCLC.

We further found that the rates of *EGFR* mutation, amplification, and protein expression were 1.7%, 19.6%, and 38.3%, respectively, and *K-Ras* mutation rate was 5.0%. Previous studies showed that the rates of *EGFR* mutation, amplification, and protein expression in patients with lung adenocarcinoma ranged from 15% to 55%, from 32.8% to 47.7%, and from 50.0% to 59.1% [@b6]--[@b8],[@b18],[@b25],[@b26], whereas *K-Ras* mutation rate ranged from 15.2% to 27.7% [@b12],[@b13]. In contrast, mutation and amplification rates of *EGFR* in LCLC patients were far lower than those in patients with lung adenocarcinoma. This may be ascribed to the high percentage of male patients (73.3%) and smokers (75.0%) in our LCLC cohorts because *EGFR* mutations primarily occur in female non-smoking patients with adenocarcinoma[@b8],[@b18],[@b24].

After statistical analysis of 1335 patients with NSCLC, Mitsudomi *et al.*[@b27] found that 70% of patients with *EGFR* mutations were responsive to EGFR-TKIs, whereas only 10% of patients with wild-type *EGFR* were responsive to EGFR-TKIs, 35% of 663 patients with high *EGFR* gene copy number were responsive to EGFR-TKIs, whereas only 9% of patients with low copy number were responsive to the same treatment. High responsiveness of patients with *EGFR* mutations and amplification to EGFR-TKIs has been confirmed in other related studies[@b6],[@b7],[@b25]. Our study found that only a few patients with LCLC contained *EGFR* mutations or high gene copy number, suggesting that only a few patients can benefit from EGFR-TKI treatment.

The positive rate of EGFR protein in NSCLC was reported in the range of 40% to 80%[@b28]. However, we observed EGFR protein in only 38.3% of LCLC patients. This may be due to low *EGFR* mutation rate or gene copy number, or to protein degradation during long storage time. Few studies suggest that EGFR protein expression is correlated with high patient responsiveness to EGFR- TKIs[@b6], most results failed to support this conclusion[@b29],[@b30]. Although this supposition is still being debated, low EGFR protein expression rate give hint that most LCLC patients can not benefit from the EGFR-TKI treatment.

###### Association between clinicopathologic variables and biomarkers in patients with large cell lung cancer

  Variable                 EGFR expression \[cases (%)\]   *EGFR* FISH \[cases (%)\]   *K-Ras* mutation \[cases (%)\]   ERCC1 expression \[cases (%)\]   VEGF expression \[cases (%)\]
  ----------------------- ------------------------------- --------------------------- -------------------------------- -------------------------------- -------------------------------
  Sex                               *P* = 0.936                   *P* = 0.669                   *P* = 0.171                      *P* = 0.582                      *P* = 0.346
   Men                               44 (61.4)                     40 (17.5)                      44 (2.3)                        44 (54.5)                        44 (65.9)
   Women                             16 (62.5)                     11 (27.2)                     16 (12.5)                        16 (62.5)                        16 (81.3)
  Age                               *P* = 0.445                   *P* = 0.353                   *P* = 1.000                      *P* = 0.660                      *P* = 0.775
   ≥ 60 years                        25 (44.0)                     19 (26.3)                      25 (4.0)                        25 (60.0)                        25 (72.0)
   \< 60 years                       35 (34.3)                     32 (15.6)                      35 (5.7)                        35 (54.3)                        35 (68.5)
  Smoking history                   *P* = 0.878                   *P* = 0.769                   *P* = 1.000                      *P* = 0.367                      *P* = 0.192
   Yes                               45 (37.8)                     39 (20.5)                      45 (4.4)                        45 (53.3)                        45 (64.4)
   No                                15 (40.0)                     12 (16.7)                      15 (6.7)                        15 (66.7)                        15 (86.6)
  Tumor diameter                    *P* = 0.552                   *P* = 1.000                   *P* = 1.000                      *P* = 1.000                      *P* = 0.212
   \< 3 cm                           3 (66.7)                       2 (0.0)                         3(0)                           3 (66.7)                        3 (33.3)
   ≥ 3 cm                            57 (36.8)                     49 (20.4)                      57 (5.3)                        57 (56.1)                        57 (71.9)
  TNM stage                         *P* = 0.822                   *P* = 0.316                   *P* = 0.258                      *P* = 0.538                      *P* = 0.052
   I--II                             35 (37.1)                     28 (14.3)                      35 (8.6)                        35 (60.0)                        35 (60.0)
   III--IV                           25 (40.0)                     23 (26.1)                       25(0)                          25 (52.0)                        25 (84.0)
  Lymph node metastasis             *P* = 0.604                   *P* = 0.781                   *P* = 1.000                      *P* = 0.700                      *P* = 0.046
   Yes                               26 (34.6)                     23 (17.3)                      26 (3.8)                        26 (53.8)                        26 (84.6)
   No                                34 (41.1)                     28 (21.4)                      34 (5.8)                        34 (58.8)                        34 (58.8)

High level of ERCC1 protein expression is a marker of resistance to platinum chemotherapy in NSCLC patients[@b3],[@b4]. Furthermore, VEGF-positive patients generally have higher responsiveness to anti-VEGF drugs than VEGF-negative patients [@b16]. Correlation of *EGFR* gene mutation, expression, or amplification status and ERCC1 protein expression have seldom been studied. Andrieux *et al*.[@b31] reported that EGFR induced ERCC1 expression via MAPK pathway in human hepatoma cells, and Kim *et al.*[@b32] showed that EGFR protein expression was positively correlated with ERCC1 expression in gastric cancer. Nevertheless, we did not find any correlation among EGFR expression, *EGFR* amplification, and ERCC1 protein expression. *EGFR* amplification was more frequently observed in patients with ERCC1 expression, suggesting that higher *EGFR* copy number may induce protein expression of ERCC1 in LCLC patients. In contrast, Lee *et al.*[@b18] reported that *EGFR* mutations were more common in ERCC1-negative NSCLC patients with squamous cell carcinomas or adenocarcinomas. These inconsistent results suggest a complicated relationship between EGFR and ERCC1 protein expression in lung cancer. Different pathologic types and *EGFR* statuses may result in distinct patterns of ERCC1 protein expression. Further study of larger scale is required to uncover their intrinsic correlations. Samples with *EGFR* amplification and without ERCC1 expression accounted for only 5.8% (3/51) of all studied cases, suggesting that only a few patients can benefit from both EGFR-TKI and platinum therapy. The fact that *EGFR* amplification was more commonly observed in ERCC1-positive samples implies that there is no overlap between LCLC patients with optimal response to EGFR-TKIs and those with optimal response to platinum-based chemotherapy. Nevertheless, the significance of this hypothesis was limited statistically by the prevalence of few samples with *EGFR* mutations. Studying patient samples on a larger scale may provide further insight into the two groups of patients and their optimal treatments.

The positive rate of VEGF in ERCC1-negative patients was as high as 65.3%, suggesting a major overlap between LCLC patients with optimal outcomes for platinum-based chemotherapy and those with optimal outcomes for anti-VEGF treatment. Combination of these two treatments may provide a greater benefit for the patients than single agents. However, it should be noted that the correlation of *EGFR* gene and VEGF protein expression is statistically meaningless, suggesting that the impact of combination therapy on clinical outcomes of the patients is still unclear.

In conclusion, low *EGFR* mutation and amplification rates suggest only a few patients with LCLC can benefit from EGFR-TKI treatment. Although correlation analysis did not find significant relationships among *EGFR, K-Ras, ERCC1*, and *VEGF* genes or protein expression status, this study suggests that patients with optimal outcomes for platinum-based chemotherapy overlapped with patients with optimal outcomes for anti-VEGF treatment rather than those for EGFR-TKI treatment. Thus, it may be useful to treat patients with lower ERCC1 expression with the combination of anti-angiogenic therapy and chemotherapy, and treat patients with higher ERCC1 expression with EGFR-TKI-targeted therapy, although this suggestion still needs supportive data from large scale clinical trials. In addition, we did not find biomarkers that affect the prognosis of LCLC, and TNM stage was the only factor that affect prognosis.
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